License Category

Setting

30 Interventions

Ofatumumab (6)

Reg. name: Arzerra®

Class: Anti-CD20 monoclonal antibody

Arzerra® is indicated in combination with chlorambucil, for the treatment of previously untreated patients with Chronic Lymphocytic Leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate

Arzerra® in combination with chlorambucil or bendamustine is indicated for the treatment of patients with Chronic Lymphocytic Leukemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy

Obinutuzumab (5)

Reg. name: Gazyvaro®, Gazyva®

Class: Anti-CD20 monoclonal antibody

Gazyva®, in combination with bendamustine followed by Gazyva® monotherapy, is indicated for the treatment of patients with Follicular Lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen

Gazyvaro® in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated Chronic Lymphocytic Leukemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy

Gazyvaro® in combination with bendamustine followed by Gazyvaro® maintenance is indicated for the treatment of patients with Follicular Lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen

Professional society

The European Lymphoma Institute is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training and education. Together they look to define strategies to analyse and characterize lymphoma and its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This all results in the advancement of lymphoma research and it guarantees equal access for all patients to the best possible care.